Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis
Authors
Keywords
-
Journal
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2016-12-05
DOI
10.1093/jjco/hyw192
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study
- (2016) Rengaswamy Sankaranarayanan et al. LANCET ONCOLOGY
- Low-event-rate meta-analyses of clinical trials: implementing good practices
- (2016) Jonathan J. Shuster et al. STATISTICS IN MEDICINE
- US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines
- (2015) Mona Saraiya et al. JNCI-Journal of the National Cancer Institute
- Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials
- (2015) Aimée R Kreimer et al. LANCET ONCOLOGY
- US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines
- (2015) Mona Saraiya et al. JNCI-Journal of the National Cancer Institute
- Conducting Meta-Analyses inRwith themetaforPackage
- (2015) Wolfgang Viechtbauer Journal of Statistical Software
- The cost–effectiveness of HPV vaccination in addition to screening: a Dutch perspective
- (2014) Didik Setiawan et al. Expert Review of Vaccines
- Expanding access to non-traditional vaccines: a perspective from Indonesia
- (2014) Auliya A Suwantika et al. Expert Review of Vaccines
- Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: Results from a randomized controlled trial
- (2014) Feng-Cai Zhu et al. INTERNATIONAL JOURNAL OF CANCER
- Long-term Immunogenicity and Safety of the HPV-16/18 AS04-adjuvanted Vaccine in 10- to 14-year-old Girls
- (2014) Tino F. Schwarz et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Long-term Study of a Quadrivalent Human Papillomavirus Vaccine
- (2014) D. Ferris et al. PEDIATRICS
- Prevention of HPV-Related Cancers in Norway: Cost-Effectiveness of Expanding the HPV Vaccination Program to Include Pre-Adolescent Boys
- (2014) Emily A. Burger et al. PLoS One
- Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial
- (2014) Tracy Pondo et al. VACCINE
- Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine
- (2014) Paulo S Naud et al. Human Vaccines & Immunotherapeutics
- Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
- (2014) Mark H Einstein et al. Human Vaccines & Immunotherapeutics
- Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study
- (2014) Mark Jit et al. Lancet Global Health
- Impact of HPV16/18 vaccination on quality of life: A pilot study
- (2013) Tiina Eriksson et al. EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE
- Evaluation of a 5-year cervical cancer prevention project in Indonesia: Opportunities, issues, and challenges
- (2013) Young-Mi Kim et al. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
- Positive Outcomes Influence the Rate and Time to Publication, but Not the Impact Factor of Publications of Clinical Trial Results
- (2013) Pilar Suñé et al. PLoS One
- Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): Health system experiences and prospects
- (2013) Jannah Wigle et al. VACCINE
- Comparatively low attendance during Human Papillomavirus catch-up vaccination among teenage girls in the Netherlands: Insights from a behavioral survey among parents
- (2012) Giedre Gefenaite et al. BMC PUBLIC HEALTH
- Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10–25-Year-Old HIV-Seronegative African Girls and Young Women
- (2012) Papa Salif Sow et al. JOURNAL OF INFECTIOUS DISEASES
- Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis
- (2012) Talía Malagón et al. LANCET INFECTIOUS DISEASES
- The Impact of Rotavirus Vaccination on Discounted Net Tax Revenue in Egypt
- (2012) Mark P. Connolly et al. PHARMACOECONOMICS
- Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, double-blind, placebo-controlled trial in Chinese males and females
- (2012) Rongcheng Li et al. VACCINE
- Efficacy and Safety of Prophylactic Vaccines against Cervical HPV Infection and Diseases among Women: A Systematic Review & Meta-Analysis
- (2011) Beibei Lu et al. BMC INFECTIOUS DISEASES
- Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment
- (2011) Aimée R. Kreimer et al. INTERNATIONAL JOURNAL OF CANCER
- Safety and Immunogenicity Profile of Human Papillomavirus-16/18 AS04 Adjuvant Cervical Cancer Vaccine: A Randomized Controlled Trial in Healthy Adolescent Girls of Bangladesh
- (2011) S. Khatun et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women
- (2011) Seung Cheol Kim et al. Journal of Gynecologic Oncology
- Performance of rotavirus vaccines in developed and developing countries
- (2010) Victoria Jiang et al. Human vaccines & immunotherapeutics
- Immunogenicity, Reactogenicity, and Safety of Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Japanese Women
- (2010) Ryo Konno et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Cervical Human Papillomavirus Prevalence in 5 Continents: Meta‐Analysis of 1 Million Women with Normal Cytological Findings
- (2010) Laia Bruni et al. JOURNAL OF INFECTIOUS DISEASES
- Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years
- (2010) Young-Jae Kim et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women
- (2010) Neerja Bhatla et al. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
- Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial
- (2009) Nubia Muñoz et al. LANCET
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
- (2009) J Paavonen et al. LANCET
- Asia Pacific: Cervical Cancer Screening and Human Papillomavirus Vaccination Policy and Delivery
- (2008) Keerti V. Shah VACCINE
- Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects
- (2007) S. KANG et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines
- (2007) Cosette M. Wheeler et al. VACCINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started